Share

Studies soon opened

Studies opened since 01 January 2009

EORTC trial 08061
Phase II study of sunitinib (SU11248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a “sensitive” relapse.

EORTC trial 22055-08053
Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement

Studies in regulatory process

EORTC trial 22043-30041
Post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus post-operative external radiotherapy alone in pathological stage pT3a-b R0-1/pT2R1 N0M0, Gleason score 5-10 prostatic carcinoma. A phase III study.

EORTC trial 26062-22061
A randomized phase III study of Temozolomide and short-course Radiation versus short-course Radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients

EORTC trial 30071
Double blind randomized phase II Trial in patients with advanced urothelial tract cancer (T3b,T4/N+/M+) of Gemcitabine and Cisplatin with Sorafenib or placebo.

EORTC trial 30072
A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse

EORTC trial 62063
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate

Back to news list

Related News

  • CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer

  • EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials

  • New study confirms a key quality of life tool can be used with adolescents with cancer

  • “Changing practice, improving lives”: EORTC publishes its Annual Report 2025

  • This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research

  • Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer

  • Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma

  • EORTC’s presence at ESTRO 2026

  • Interview of ROSC Chair, Joost Vaerhoeff

  • Independent, academic cancer trials are vital to improve patient outcomes worldwide